Categories: Company News

Ranbaxy stops shipments from Toansa, Dewas plants

New Delhi February 26, 2014:- Ranbaxy Laboratories has halted all shipments of pharmaceutical ingredients from its Toansa and Dewas plants.

In a statement to the BSE on Tuesday, the company said it is examining processes and controls at all its active pharmaceutical ingredients (API) manufacturing and quality units. The decision comes in the backdrop of the recent US ban on products manufactured at these units. The move is likely to hit supplies to Ranbaxy’s other key markets, including Europe. Both plants — Toansa in Punjab, and Dewas in Madhya Pradesh — along with two more plants, Paonta Sahib in Himachal Pradesh and Mohali in Punjab, have been banned from exporting pharmaceutical ingredients as well as finished goods to the US.

While announcing its results for the fourth quarter recently, Ranbaxy had said the US ban on the Toansa plant had hit the company’s sales by 10-15 per cent.

“Since, the company has voluntarily withdrawn its production; we believe that it would have made alternative arrangements for production,” said Sarabjit Kour Nangra, Vice-President (Research), Pharma, Angel Broking.

Another industry expert said Ranbaxy would most probably have to procure drug ingredients from other companies in order to continue manufacturing finished medicines and this would push up costs for the company, hitting its margins.

The drug major said this voluntary action has been taken as a “precautionary measure” and shipments will be resumed after all processes have been assessed.

“A committee of the Board has been constituted … to help and assure good governance to all Ranbaxy stakeholders,” the company said in a statement.

The pharma major’s shares rose 0.99 per cent on the BSE to close at ₹367.05 apiece on Tuesday.- Business Line

The Pharma Times News Bureau

Recent Posts

New medical nutrition ingredient combines high-protein with “best taste yet”

New Delhi, November 06, 2024: Arla Foods Ingredients has launched a new whey protein hydrolysate…

13 hours ago

6 Early Signs of Ovarian Cancer

By Dr. C N Patil, HOD and Lead Consultant - Medical Oncology & Haemato-Oncology, Aster…

13 hours ago

Bayer Introduces Bepanthen in India as New Survey Reveals Dry Skin Affects 1 in 2 Indians

·        World's no.1 skincare brand Bepanthen* launches in India, as a solution to tackle India's widespread dry skin…

2 days ago

Lung Cancer in India: Understanding Risk Factors and the Importance of Early Detection

By Dr. Pavan Yadav, Lead Consultant - Interventional Pulmonology & Lung Transplantation, Aster RV Hospital.…

2 days ago

10 Winter Skin Care Tips Dermatologists Swear By

Dr. Priyanka Kuri, Consultant - Dermatology, Aster Whitefield Hospital, Bengaluru  Winter weather brings a host…

5 days ago

Fighting Viral Hepatitis in India: Prevention, Risks, and the Path to Better Health

By Dr. Naveen Ganjoo, Senior Consultant - Hepatology & Integrated Liver Care, Aster RV Hospital…

6 days ago